Our latest articles

Vantage logo

Abbvie takes its Treg cue

The big pharma becomes the latest to look at IL-2 to harness regulatory T cells, but plenty of others have the same idea.

Vantage logo

Pressure piles up on pamrevlumab

After the latest roxadustat clanger a phase 3 interim analysis in pancreatic cancer becomes even more important for Fibrogen.